An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

March 20, 2023

Study Completion Date

March 20, 2023

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

spesolimab

solution for infusion

Trial Locations (9)

467-8602

Nagoya City University Hospital, Aichi, Nagoya

814-0180

Fukuoka University Hospital, Fukuoka, Fukuoka

890-8520

Kagoshima University Hospital, Kagoshima, Kagoshima

514-8507

Mie University Hospital, Mie, Tsu

980-8574

Tohoku University Hospital, Miyagi, Sendai

350-0495

Saitama Medical University Hospital, Saitama, Iruma-gun

329-0498

Jichi Medical University Hospital, Tochigi, Shimotsuke

173-8606

Teikyo University Hospital, Tokyo, Itabashi-ku

160-0023

Tokyo Medical University Hospital, Tokyo, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05200247 - An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Biotech Hunter | Biotech Hunter